Luminex Receives FDA Clearance for an Update to the xTAG(R) Respiratory Viral Panel Package Insert

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared labeling updates for the company’s xTAG® Respiratory Viral Panel (RVP) to include data about the performance of the test in humans infected with the pandemic strain of influenza A, 2009 influenza A/H1N1, which is sometimes referred to as “swine flu.” The test’s labeling has been updated to include information from two new studies that demonstrate that xTAG RVP can be an effective aid in the detection of 2009 Influenza A/HIN1, but cannot identify the hemagglutinin gene of the 2009 Influenza A/H1N1 in clinical specimens

Source: Luminex